EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Capecitabine monotherapy versus CapeOX regimen in adjuvant chemotherapy for elderly patients with colon cancer: a single-center propensity-matched study

Yan Ye, Yu-lian Huang, Hai-long Wang, Yi-hui Lei

Frontiers in Oncology · 20.11.2026 · 16

DOI: 10.3389/fonc.2026.1956254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.11.2026. Verfasst von Yan Ye und 3 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal adjuvant chemotherapy for elderly patients with colon cancer remains controversial. This retrospective study aimed to compare the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) versus capecitabine monotherapy in this population.

Methods

This retrospective study included patients aged ≥65 years with high-risk stage II or stage III colon cancer and proficient mismatch repair status who were treated at Xiamen Humanity Hospital. Patients received either CapeOX or capecitabine monotherapy. One-to-one propensity score matching was performed based on age, tumor stage, tumor differentiation, number of chemotherapy cycles, and the Charlson Comorbidity Index as matching variables. Disease-free survival (DFS) and chemotherapy-related adverse events were then compared between the matched treatment groups.

Results

A total of 398 patients were included in the study (CapeOX, n=252; capecitabine, n=146). After propensity score matching, 110 patients remained in each group. No significant difference was observed in 5-year DFS rate between the CapeOX and capecitabine groups (70.9% vs. 77.3%, p=0.306). Compared with the capecitabine monotherapy group, the CapeOX group had a significantly higher incidence of grade ≥2 adverse events (49.1% vs. 25.5%, p=0.010). In the Cox regression analysis, patients who received ≥6 cycles of chemotherapy had a significantly lower risk of disease recurrence (HR = 0.50, 95% CI: 0.29–0.86, p = 0.011). Further analysis of the association between the number of chemotherapy cycles and DFS showed that, among patients with stage III colon cancer receiving capecitabine monotherapy, completion of ≥6 cycles of chemotherapy was associated with a significantly lower risk of recurrence (HR = 0.26, 95% CI: 0.08–0.82, p = 0.022).

Conclusion

In this analysis, no significant difference in DFS was observed between the CapeOX and capecitabine monotherapy groups. However, the capecitabine monotherapy group had a significantly lower incidence of grade ≥2 adverse events. Moreover, completion of ≥6 cycles of chemotherapy was associated with a significantly reduced risk of recurrence compared with receiving fewer than 6 cycles. For elderly patients with stage III colon cancer, completing ≥6 cycles of capecitabine monotherapy may be associated with favorable DFS outcomes. These findings require confirmation in larger prospective studies.

Zitieren

APA

Ye, Y., Huang, Y., Wang, H., & Lei, Y. (2026). Capecitabine monotherapy versus CapeOX regimen in adjuvant chemotherapy for elderly patients with colon cancer: a single-center propensity-matched study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1956254

Vancouver

Ye Y, Huang Y, Wang H, Lei Y. Capecitabine monotherapy versus CapeOX regimen in adjuvant chemotherapy for elderly patients with colon cancer: a single-center propensity-matched study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1956254

BibTeX
@article{Ye2026,
  author = {Ye, Yan and Huang, Yu-lian and Wang, Hai-long and Lei, Yi-hui},
  title = {Capecitabine monotherapy versus CapeOX regimen in adjuvant chemotherapy for elderly patients with colon cancer: a single-center propensity-matched study},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1956254}
}
Kostenlos starten →